- S&P/TSX14,795.13-0.95%
- S&P 5002,633.08-2.33%
- DOW24,388.95-2.24%
- CAD/USD0.7500+0.4072%
- CRUDE OIL52.13+1.24%
- BTC-CAD5,124.27+6.10%
- GOLD FUTURES1,249.40+0.91%
- RUSSELL 20001,448.09-1.98%
- 10-Yr Bond2.8500-0.90%
- NASDAQ6,969.25-3.05%
- VOLATILITY23.23+9.63%
- FTSE6,778.11+1.10%
- NIKKEI 22521,678.68+0.82%
- CAD/EUR0.6579+0.24%
Cannabis Stocks
39.31k followers • 23 symbols +5.41% Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
23 Symbols
Get the Yahoo Finance app
- Free real-time data
- News and price alerts
- Add and edit holdings
- Track performance
- Create multiple watchlists
- Motley Fool•3 hours ago
The Craziest Marijuana Statistic of 2018
Despite no shortage of cannabis milestones, it was an odd year for pot stocks.
- Motley Fool•6 hours ago
2 Must-Read Quotes on Marijuana From FDA Head Scott Gottlieb
Is cannabis policy reform at the federal level "inevitable?"
- Motley Fool•6 hours ago
3 Top Stocks to Buy in December
These stocks have one common denominator: Great long-term growth prospects.
- Motley Fool•6 hours ago
Why Aurora Cannabis, Canopy Growth, and Tilray Have Had a Better Year Than You Might Think
There's more to the story for these Canadian marijuana stocks' gains -- or lack thereof -- in 2018.
- Motley Fool•6 hours ago
Better Marijuana Stock: Cronos Group vs. GW Pharmaceuticals
Which stock wins in a matchup between this top Canadian marijuana grower and the biggest cannabis-focused biotech?
- Motley Fool•8 hours ago
Did Gilead Sciences Make an $11 Billion Blunder?
Spoiler alert: The answer is "no."
- The Motley Fool•19 hours ago
Is It Time to Buy Marijuana Stocks?
Marijuana stocks continue their wild ride as Altria Group Inc. (TSX:MO) buys 45% stake in Cronos Group Inc. (TSX:CRON) (NYSE:CRON) and take them higher on Friday after a week of continued marijuana stock carnage.
- Motley Fool•21 hours ago
Here's Why Scotts Miracle-Gro Rose 13.8% in November
The home garden specialist announced fiscal 2018 earnings and issued upbeat guidance for fiscal 2019.
- Motley Fool•yesterday
Better Marijuana Stock: Aurora Cannabis vs. KushCo Holdings
Which stock wins in a matchup between a big marijuana producer and a top ancillary products supplier to the cannabis industry?
- Motley Fool•yesterday
4 Multibillion-Dollar Industries Canopy Growth Thinks It Will Disrupt
Are Canopy's plans to jump into multiple huge markets only pipe dreams? Not at all.
- The Motley Fool•yesterday
Have Weed Stocks Replaced Bitcoin?
Lessons that Canopy Growth Corporation (TSX:WEED) can learn from cryptocurrencies
- Motley Fool•2 days ago
Better Buy: Scotts Miracle-Gro vs. Lowe's
There are two factors to consider when looking at Lowe's and Miracle-Gro: recent performance and marijuana.
Market Realist•2 days agoA Look at AbbVie’s Earnings Projections for 2018
On its third-quarter earnings conference call, AbbVie (ABBV) raised its adjusted EPS guidance for 2018 from its previous projection of $7.76–$7.86 to $7.90–$7.92. The revised estimate implies a YoY (year-over-year) rise of 41.3% considering the midpoint of the guidance range. As per the company’s third-quarter earnings conference call, AbbVie expects its adjusted fourth-quarter EPS to be in the range of $1.89–$1.91 excluding a $0.26 impact of noncash amortization and other items.
- The Canadian Press•2 days ago
Most actively traded companies on the TSX
Some of the most active companies traded Friday on the Toronto Stock Exchange:
Market Realist•2 days agoWhy Aphria Tanked Over 11% Today
Today, Aphria (APHA)(APHQF) resumed a sharp sell-off in its stock from early this month after surging a whopping 51% yesterday. Now, let’s find out what could be driving Aphria stock down today. Grego alleged that “Aphria had diverted funds into inflated investments held by insiders.” Since then, these allegations have taken a massive toll on investors’ confidence.
Market Realist•2 days agoAssessing AbbVie’s 2018 Revenue Projections
On its third-quarter earnings conference call, AbbVie (ABBV) raised its net revenue guidance for 2018 from its previous projection of $32.5 billion to $32.7 billion. The company also raised its forecast for YoY (year-over-year) operational revenue growth in 2018 from 14.5% to 15.0%. As per AbbVie’s third-quarter earnings conference call, the company expects a favorable revenue impact of less than 1% due to foreign currency fluctuations in 2018.
- The Canadian Press•2 days ago
Aurora Cannabis to supply medical pot to Mexico through partnership
EDMONTON — Aurora Cannabis says it will supply medical cannabis to Mexico through a partnership with pharmaceutical manufacturer and distributor Farmacias Magistrales.
- Reuters•2 days ago
Aurora Cannabis to supply medical marijuana to Mexico
"This new exclusive partnership further expands Aurora's early mover advantage in Latin America," Chief Executive Officer Terry Booth said in a statement. Farmacias has a reach of about 80,000 retail points and 500 pharmacies and hospitals across Mexico, the company said. The announcement comes a month after Mexico's Congress website showed its plans to submit a bill to create a medical marijuana industry and allow recreational use in what would be a big step by the incoming government to shake up the country's drug war.
Market Realist•2 days agoAnalysts’ Recommendations for AbbVie in December
The company saw a rise of 17.53% in its share price from $80.21 on November 1 to $94.27 on November 30. Thereafter, AbbVie saw a 3.95% fall in its share price from November 30 to December 5. On November 30, AbbVie issued a press release announcing agreements that granted Pfizer (PFE) a nonexclusive global license related to Humira’s intellectual property.
- Investing.com•2 days ago
AbbVie Falls 4%
Investing.com - AbbVie (NYSE:ABBV) fell by 4.11% to trade at $86.620 by 11:29 (16:29 GMT) on Friday on the NYSE exchange.
- Market Realist•2 days ago
Short Seller Not Backing Down on Aphria
On December 6, Aphria’s (APHQF) short seller, Hindenburg Research, released its Part 2 on what it found to be further malice in the company’s acquisition efforts. According to the research, this acquisition showed a 5 million Canadian dollar gain to Aphria’s insider in a matter of six days. Further, the report pointed out that Aphria’s CEO, Vic Neufeld, was also a part of the “discount round” in which Aphria purchased companies at overpriced valuations. Even more damning was the short seller’s observation that the SEC had alleged that the individuals that Aphria purchased companies from were involved in pump and dump schemes.
- Yahoo Finance•2 days ago
Weed CEO: 'Edibles suffer from 3 major problems'
Edibles still quite aren't mainstream for various reasons, an edibles CEO tells Yahoo Finance recently on the Final Round.
- Yahoo Finance•2 days ago
Stocks tumble, oil surges on OPEC deal
Yahoo Finance's LIVE market coverage and analysis, beginning each day at 11:30 a.m. ET.
- The Motley Fool•2 days ago
Beware: Canopy Growth Corp. (TSX:WEED) Is Cheaper, but Not Cheap
Even though the stock has come down significantly in price, Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) is cheaper than it once was, but it is by no means cheap.
- Market Realist•2 days ago
Aphria’s Announcement of Special Committee Pauses Sell-Off
Aprhia (APHQF) recovered by nearly 50% on December 6 due to its further commitment to relieve investors’ fears related to its Latin America business. The company appointed a special committee that consists of independent directors who will be tasked with reviewing the legitimacy of the company’s acquisitions in Latin America. The above chart shows that Aphria (APHQF) is among the top ten holdings in the Horizons Marijuana Life Sciences ETF (HMMJ).
